Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...

除了一些明显的抛售之外，2024 年是股市大涨的一年。年初至今，基准标普 500 指数上涨了近 24%，道琼斯工业平均指数上涨了 13%。科技股重镇纳斯达克综合指数飙升了近 30%。

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...

LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...